Valuation: Natera, Inc.

Market Cap 44.67B 38.59B 36.26B 32.98B 62B 4,272B 63.02B 425B 166B 2,139B 168B 164B 7,109B P/E 2026 *
-224x
P/E 2027 * -11,509x
Enterprise Value 43.6B 37.66B 35.39B 32.18B 60.51B 4,170B 61.51B 415B 162B 2,088B 164B 160B 6,939B EV / Sales 2026 *
15x
EV / Sales 2027 * 12.5x
Free-Float
97.5%
Yield 2026 *
-
Yield 2027 * -
1 day+2.25%
1 week-3.73%
Current month+13.63%
1 month+13.15%
3 months+64.03%
6 months+54.59%
Current year+34.97%
1 week 264.9
Extreme 264.9
280
1 month 218.5
Extreme 218.5
280
Current year 158
Extreme 158
280
1 year 158
Extreme 158
280
3 years 158
Extreme 158
280
5 years 84
Extreme 84
280
10 years 6.62
Extreme 6.615
280
Manager TitleAgeSince
Chief Executive Officer 47 02/01/2019
President 46 01/09/2023
Director of Finance/CFO 45 01/02/2017
Director TitleAgeSince
Chairman 53 01/05/2015
Director/Board Member 53 01/01/2007
Director/Board Member 47 02/01/2019
Change 5-day change 1-year change 3-year change Capi.($)
+2.27%-3.73% - - 44.67B
+1.86%-1.01%+95.56%+506.39% 44.67B
+1.66%+0.39%+19.25%+51.50% 25.8B
+1.97%+1.83%-19.96%-28.79% 7.84B
-0.18%-1.22%+15.15%+160.17% 6.01B
-2.04%-3.93%+9.51%+66.25% 3.35B
+1.02%+0.89%-37.59%+1,428.60% 2.33B
-1.57%+3.76%-0.33%-53.47% 2.06B
+1.29%-3.13%+158.17%+17.94% 2.05B
-0.49%-3.40%+28.30%+20.40% 1.89B
Average +0.61%-0.90%+29.78%+241.00% 10.67B
Weighted average by Cap. +1.74%-1.67%+52.30%+293.76%

Financials

2026 *2027 *
Net sales 2.9B 2.5B 2.35B 2.14B 4.02B 277B 4.09B 27.58B 10.78B 139B 10.89B 10.65B 461B 3.47B 3B 2.82B 2.56B 4.82B 332B 4.89B 33B 12.9B 166B 13.03B 12.74B 552B
Net income -194M -168M -158M -143M -269M -18.57B -274M -1.85B -722M -9.3B -729M -713M -30.9B 4.91M 4.24M 3.98M 3.62M 6.81M 469M 6.92M 46.67M 18.25M 235M 18.43M 18.03M 781M
Net Debt -1.07B -925M -869M -790M -1.49B -102B -1.51B -10.18B -3.98B -51.27B -4.02B -3.93B -170B -1.36B -1.18B -1.11B -1.01B -1.89B -130B -1.92B -12.96B -5.07B -65.25B -5.12B -5B -217B
Logo Natera, Inc.
Natera, Inc. provides cell-free DNA (cfDNA) and genetic testing, dedicated to oncology, women’s health, and organ health. The Company's cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and artificial intelligence. It has leveraged its platform to develop non-invasive prenatal test on the market (Panorama), the first tumor-specific assay for truly individualized cancer care (Signatera), best-in-class rejection assessment for kidney transplantation (Prospera) and others. In the women’s health space, it develops and commercializes non- or minimally- invasive tests to evaluate risk for, and thereby enable early detection of, a range of genetic conditions, such as Down syndrome. In oncology, it is focused on detecting molecular residual disease and recurrence monitoring in solid tumors, among others. In organ health, it offers tests to assess kidney, heart, and lung transplant rejection as well as genetic testing for chronic kidney disease.
Employees
6,138
Date Price Change Volume
17/08/26 265.90 -0.37% 0
14/08/26 €266.90 -4.68% 0
13/08/26 €280.00 +4.28% 20
12/08/26 €268.50 -4.11% 9
11/08/26 €280.00 +1.38% 50
Trader
Investor
-
Global
-
Quality
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
309.93USD
Average target price
330.64USD
Spread / Average Target
+6.68%

Quarterly revenue - Rate of surprise